Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1Melanoma 1Immunologic Deficiency Syndromes 1IgA Deficiency 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × B-Cell Activating Factor × Clear all
NCT00024934 2016-09-22

B-Lymphocyte Stimulator (BLyS) To Treat Selective IgA Deficiency

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
20 enrolled

Immunologic Deficiency Syndromes, Neoplasms, IgA Deficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡